First European hypercare launch site initiated following CE mark approval Initial Serological Disease Screening microarray submitted for CE marking U.S. field trial activities for initial Serological Disease Screening commenced 13 blood grouping reagents approved by the FDA for use with OEM
JERSEY, Channel Islands , July 22, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2019, will be released before market open on Monday, August 5, 2019.
JERSEY, Channel Islands , July 02, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced the Board of Directors’ decision to amend Chief Executive Officer (CEO) Franz Walt’s employment
JERSEY, Channel Islands , July 01, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced the submission of its completed dossier for the CE Mark (Conformité Européenne) of its initial
JERSEY, Channel Islands , June 05, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop , will present at the inaugural Raymond James Life Sciences and MedTech Conference on
CE mark received on the initial Immunohematology microarray in April 2019 2018 manufacturing site certification and MosaiQ™ device CE mark combine with the recent approval to permit commercialization Successful European field trial drives the expectation of CE mark submission for the initial
JERSEY, Channel Islands , May 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop , will present at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 8:30
JERSEY, Channel Islands , May 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), an established, commercial-stage diagnostics company (the Company), today announced the U.S. Food and Drug Administration ( FDA ) has approved the commercialization of seven additional blood bank reagents
JERSEY, Channel Islands , May 14, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2019 will be released before market open on Tuesday, May 28, 2019 .
JERSEY, Channel Islands , May 01, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced receipt of the CE Mark (Conformité Européenne) for its initial Immunohematology (IH) Microarray for
